In 2014, nivolumab and pembrolizumab (PD-1 blockade) were approved by the FDA as a humanized IgG antibody for the treatment of unresectable or metastatic melanoma (Prasad and Kaestner, 2017; Finkelmeier et al., 2018). Here, PDCD1 is linked to metastatic melanoma.